Zentalis Pharmaceuticals, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
Zentalis Pharmaceuticals, Inc. (ZNTL) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $15.00 thousand as of 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Notes
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2020-08-13
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $15.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2020-06-30 | $15.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |